Propylthiouracil
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Propylthiouracil
|
|
| Systematic (IUPAC) name | |
| 6-propyl-2-sulfanyl-pyrimidin-4-ol | |
| Identifiers | |
| CAS number | |
| ATC code | H03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C7H10N2OS |
| Mol. mass | 170.233 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 2 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
? |
| Routes | Oral |
Propylthiouracil (PTU) is a thionamide drug used to treat hyperthyroidism. It is a medicine that is used to decrease the amount of thyroid hormone produced by the thyroid gland. PTU inhibits many steps in the synthesis of thyroid hormones, including the addition of iodide to thyroglobulin by the enzyme thyroperoxidase, a necessary step in the synthesis of thyroxine, and by inhibiting the enzyme 5'-deiodinase which converts T4 to T3.
Notably, PTU does not inhibit the action of the sodium-dependent iodide transporter located on follicular cells' basolateral membranes. Inhibition of this step requires competitive inhibitors such as perchlorate and thiocyanate.
As side effects, can cause agranulocytosis, allergic reactions, whitening and loss of hair.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
